Referencias
1. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258 (5090):1946-9. DOI: 10.1126/science.1470919.
2. O'Shaughnessy WB. On the Preparations of the Indian Hemp, or Gunjah: Cannabis Indica Their Effects on the Animal System in Health, and their Utility in the Treatment of Tetanus and other Convulsive Diseases. Prov Med J Retrosp Med Sci. 1843;5(123):363-9.
3. Mechoulam R, Gaoni Y. A Total Synthesis Of Dl-Delta-1-Tetrahydrocannabinol, The Active Constituent Of Hashish. J Am Chem Soc. 1965;87:3273-5. DOI: 10.1021/ja01092a065.
4. Mechoulam R, Shvo Y. Hashish. I. The structure of cannabidiol. Tetrahedron. 1963;19(12):2073-8. DOI: 10.1016/0040-4020(63)85022-x.
5. IASP Position Statement of the Use of Cannabinoids to Treat Pain [Internet]. IASP, 2021. Disponible en: https://www.iasp-pain.org/publications/iasp-news/iasp-position-statement-on-the-use-of-cannabinoids-to-treat-pain/
6. Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547-64. DOI: 10.1002/ejp.1297.